Healthcare provider profile · identity verified

Gregory A. Russell, MD

Family Practice · MIDLAND, NC · NPI 1992770515

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	481	139
Amlodipine Besylate	Amlodipine Besylate	383	108
Lisinopril	Lisinopril	262	71
Metoprolol Succinate	Metoprolol Succinate	232	62
Omeprazole	Omeprazole	201	64
Levothyroxine Sodium	Levothyroxine Sodium	194	53
Gabapentin	Gabapentin	190	50
Losartan Potassium	Losartan Potassium	181	54
Albuterol Sulfate Hfa	Albuterol Sulfate	174	40
Pantoprazole Sodium	Pantoprazole Sodium	173	55
Metformin Hcl Er	Metformin Hcl	162	47
Tizanidine Hcl	Tizanidine Hcl	144	29
Rosuvastatin Calcium	Rosuvastatin Calcium	141	48
Meloxicam	Meloxicam	136	46
Tamsulosin Hcl	Tamsulosin Hcl	131	37
Pravastatin Sodium	Pravastatin Sodium	125	36
Hydrochlorothiazide	Hydrochlorothiazide	120	37
Metformin Hcl	Metformin Hcl	117	35
Trazodone Hcl	Trazodone Hcl	112	32
Furosemide	Furosemide	106	33
Carvedilol	Carvedilol	104	22
Duloxetine Hcl	Duloxetine Hcl	100	24
Escitalopram Oxalate	Escitalopram Oxalate	100	25
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	95	22
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	91	22
Eliquis	Apixaban	87	21
Mirtazapine	Mirtazapine	85	21
Tramadol Hcl	Tramadol Hcl	84	23
Metoprolol Tartrate	Metoprolol Tartrate	83	21
Fluticasone Propionate	Fluticasone Propionate	79	33
Ozempic	Semaglutide	75	18
Clonazepam	Clonazepam	68	13
Sertraline Hcl	Sertraline Hcl	68	22
Bupropion Xl	Bupropion Hcl	61	23
Finasteride	Finasteride	61	12
Glipizide Er	Glipizide	57	12
Ondansetron Odt	Ondansetron	56	18
Montelukast Sodium	Montelukast Sodium	55	15
Potassium Chloride	Potassium Chloride	55	23
Allopurinol	Allopurinol	54	15
Venlafaxine Hcl Er	Venlafaxine Hcl	53	13
Jardiance	Empagliflozin	52	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	51	suppressed
Baclofen	Baclofen	50	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	49	11
Doxycycline Monohydrate	Doxycycline Monohydrate	49	45
Buspirone Hcl	Buspirone Hcl	47	suppressed
Clopidogrel	Clopidogrel Bisulfate	45	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	45	11
Glimepiride	Glimepiride	44	15
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	43	suppressed
Pregabalin	Pregabalin	43	14
Hydralazine Hcl	Hydralazine Hcl	42	12
Klor-Con M20	Potassium Chloride	41	14
Tresiba Flextouch U-100	Insulin Degludec	38	suppressed
Symbicort	Budesonide/Formoterol Fumarate	37	suppressed
Atenolol	Atenolol	36	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	35	suppressed
Ezetimibe	Ezetimibe	34	11
Celecoxib	Celecoxib	32	11
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	31	suppressed
Cephalexin	Cephalexin	31	27
Lovastatin	Lovastatin	31	suppressed
Warfarin Sodium	Warfarin Sodium	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	29	suppressed
Famotidine	Famotidine	28	suppressed
Promethazine Hcl	Promethazine Hcl	27	suppressed
Alprazolam	Alprazolam	26	suppressed
Meclizine Hcl	Meclizine Hcl	25	13
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Spironolactone	Spironolactone	25	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Chlorthalidone	Chlorthalidone	24	suppressed
Prednisone	Prednisone	24	20
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Mounjaro	Tirzepatide	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	22	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Januvia	Sitagliptin Phosphate	21	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	21	suppressed
Ondansetron Hcl	Ondansetron Hcl	21	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	20	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	suppressed
Lorazepam	Lorazepam	20	suppressed
Nitroglycerin	Nitroglycerin	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Ibandronate Sodium	Ibandronate Sodium	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Topiramate	Topiramate	18	suppressed
Alendronate Sodium	Alendronate Sodium	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Simvastatin	Simvastatin	17	suppressed
Solifenacin Succinate	Solifenacin Succinate	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Tradjenta	Linagliptin	15	suppressed
Flecainide Acetate	Flecainide Acetate	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	13
Diazepam	Diazepam	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Methimazole	Methimazole	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Spiriva Handihaler	Tiotropium Bromide	13	suppressed
Acetazolamide	Acetazolamide	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Methylprednisolone	Methylprednisolone	12	12
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	11	suppressed
Bupropion Hcl	Bupropion Hcl	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed
Ssd	Silver Sulfadiazine	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error